GlassScriptPhysician profile
Lisa Johnson Kirk
NPI 1578562146
$2,821.27
in general payments reported to CMS, 2019-2025
28 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $463 · 2021: $600 · 2022: $446 · 2023: $340 · 2024: $308 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Entertainment: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.04 |
| Entertainment | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $773.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $393.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $322.35 | 2021-2025 | |
| Amarin Pharma, INC. | $189.13 | 2019-2022 | |
| Kaleo, INC. | $167.12 | 2020-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $149.26 | 2019-2021 | |
| Allergan, INC. | $93.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $83.24 | 2020-2024 | Gardasil, M-M-R II, Gardasil 9 |
| Indivior INC. | $75.56 | 2019-2022 | |
| Amgen INC. | $71.40 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $61.43 | 2023-2024 | Veozah |
| Pfizer INC. | $57.42 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $57.07 | 2024-2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.71 | 2022-2023 | Xifaxan |
| Therapeuticsmd, INC. | $31.82 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $27.92 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $27.72 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.96 | 2021-2022 | |
| Tris Pharma INC | $22.55 | 2019 | |
| Galderma Laboratories, L.P. | $21.05 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.05 | 2020 | |
| Amag Pharmaceuticals, INC. | $20.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.52 | 2025 | Rexulti |
| Antares Pharma, INC. | $16.53 | 2022 | |
| Corcept Therapeutics | $15.30 | 2022 | |
| Optos, INC. | $14.52 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| E.R. Squibb & Sons, L.L.C. | $12.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.